Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia

Pediatrics

Volumn 122, Issue 6, 2008, Pages

  Willot, Stephanie ^a   Uhlen, Stephanie ^a   Michaud, Laurent ^a   Briand, Gilbert ^b   Bonnevalle, Michel ^a   Sfeir, Rony ^a   Gottrand, Frederic ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Bile acids; Biliary atresia; Cholestasis; Cirrhosis; Liver enzymes; Portoenterostomy; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHENODEOXYCHOLIC ACID; CHOLIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ARTICLE; BILE ACID BLOOD LEVEL; BILE DUCT ATRESIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; JAUNDICE; LIVER FUNCTION; MALE; PORTOENTEROSTOMY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; ENZYMOLOGY; HOSPITALIZATION; INFANT; LIVER; LIVER FUNCTION TEST; METHODOLOGY; MORTALITY; NEWBORN; NONPARAMETRIC TEST; PROBABILITY; PROSPECTIVE STUDY;

BILIARY ATRESIA; CHOLAGOGUES AND CHOLERETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LIVER; LIVER FUNCTION TESTS; MALE; PORTOENTEROSTOMY, HEPATIC; PROBABILITY; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; URSODEOXYCHOLIC ACID;

EID: 58249091189     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-0986     Document Type: Article

References (31)

1. Chardot C, Carton M, Spire-Bendelac N, Le Pommelet C, Gol-mard JL, Auvert B. Epidemiology of biliary atresia in France: a national study 1986-96. J Hepatol. 1999;31(6):1006-1013
2. Chardot C, Carton M, Spire-Bendelac N, Le Pommelet C, Gol-mard JL, Auvert B. Prognosis of biliary atresia in the era of liver transplantation: French national study from 1986 to 1996. Hepatology. 1999;30(3):606-611
3. McKiernan PJ, Baker AJ, Kelly DA. The frequency and outcome of biliary atresia in the UK and Ireland. Lancet. 2000; 355(9197):25-29
4. Karrer FM, Price MR, Bensard DD, et al. Long-term results with the Kasai operation for biliary atresia. Arch Surg. 1996;131(5): 493-496
5. Otte JB, de Ville de Goyet J, Reding R, et al. Sequential treatment of biliary atresia with Kasai portoenterostomy and liver transplantation. Hepatology. 1994;20(1 pt 2):41S-48S
6. Lykavieris P, Chardot C, Sokhn M, Gauthier F, Valayer J, Bernard O. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology. 2005;41(2):366-371
7. Howard ER, MacLean G, Nio M, Donaldson N, Singer J, Ohi R. Survival patterns in biliary atresia and comparison of quality of life of long-term survivors in Japan and England. J Pediatr Surg. 2001;36(6):892-897
8. DeRusso PA. Adjuvant medical therapies after portoentero-stomy for biliary atresia: time for randomized controlled trial. J Pediatr Gastroenterol Nutr. 2003;37(5):634-635
9. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991; 324(22):1548-1554
10. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994;330(19):1342-1347
11. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology. 1996;110(5): 1515-1518
12. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxy-cholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121(4):900-907
13. Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(5): 1558-1562
14. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial: the Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatol-ogy. 1996;23(6):1484-1490
15. Colombo C, Setchell KD, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr. 1990;117(3):482-489
16. Jacquemin E, Hermans D, Myara A, et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahe-patic cholestasis. Hepatology. 1997;25(3):519-523
17. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxy-cholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology. 1996; 111(3):716-719
18. De Marco G, Sordino D, Bruzzese E, Di Caro S, Mambretti D, Tramontano A, et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. Aliment Pharmacol Ther. 2006; 24(2):387-394
19. Ullrich D, Rating D, Schroter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet. 1987;2(8571): 1324
20. Nittono H, Tokita A, Hayashi M, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother. 1989;43(1):37-41
21. El-Rifai N, Gottrand F. Role of ursodeoxycholic acid in pediatric cholestatic disease. Gastroenterol Clin Biol. 2004;28(10 pt 1):852-859
22. Setchell KDR, Worthington J. A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse-phase octadecylsilane bonded silica cartridges. Clin Chim Acta. 1982;125(2):135-144
23. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr. 1997;24(5):573-589
24. A-KaderHH, Santangelo JD, Setchell KDR, Heubi JE, Ryckman FC, Balistreri WF. The effects of ursodeoxycholic acid therapy in biliary atresia: a double blind, randomised, placebo controlled trial [abstract]. Pediatr Res. 1993;33(4):97A
25. Poupon RE, Chretien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology. 1993;17(4):599-604
26. Heuman DM. Hepatoprotective properties of ursodeoxycholic acid. Gastroenterology. 1993;104(6):1865-1870
27. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001;35(1):134-146
28. Lacaille F, Paradis K. The immunosuppressive effect of ursode-oxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology. 1993;18(1):165-172
29. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990;11(1):12-15
30. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gas-troenterol Nutr. 2003;37(1):4-21
31. Frezza EE, Gerunda GE, Plebani M, et al. Effect of ursodeoxy-cholic acid administration on bile duct proliferation and cho-lestasis in bile duct ligated rat. Dig Dis Sci. 1993;38(7):1291-1296